

MERCK LIMITED
 Regd. Office: Shivasagar Estate 'A', Dr. Annie Besant Road, Worli, Mumbai - 400018
STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER ENDED 31ST MARCH, 2013

Particulars	(Rs. in Lakhs)			
	3 months ended 31/03/2013	Preceding 3 months ended 31/12/2012	Corresponding 3 months ended 31/03/2012 in the previous year	Previous year ended 31/12/2012
	Unaudited	Audited	Unaudited	Audited
1. Income from operations				
a) Net Sales/Income from operations (Net of excise duty)	17,864.87	16,117.94	13,673.57	65,807.05
b) Other operating income	538.81	638.70	963.37	2,920.90
Total income from operations (net)	18,203.68	16,756.64	14,636.94	68,727.95
2. Expenses				
a) Cost of materials consumed	6,333.58	4,352.78	3,995.19	17,943.63
b) Purchases of stock-in-trade	2,936.54	3,068.71	2,791.04	11,608.69
c) Changes in inventories of finished goods, work-in-progress and stock in trade	(1,309.41)	(126.75)	(703.04)	349.14
d) Employee benefits expense	2,330.81	1,747.57	2,276.80	8,530.07
e) Depreciation and amortisation expense	235.80	240.42	209.17	889.77
f) Other expenses	6,172.73	5,180.00	4,642.74	19,747.21
Total expenses	16,700.05	14,462.73	13,211.90	59,068.51
3. Profit from operations before other income, finance costs and exceptional items (1-2)	1,503.63	2,293.91	1,425.04	9,659.44
4. Other Income	555.25	588.23	428.22	2,019.56
5. Profit from ordinary activities before finance costs and exceptional items (3+4)	2,058.88	2,882.14	1,853.26	11,679.00
6. Finance Cost	-	-	-	-
7. Profit from ordinary activities after finance costs but before exceptional items (5-6)	2,058.88	2,882.14	1,853.26	11,679.00
8. Exceptional items	-	-	-	-
9. Profit from ordinary activities before tax (7+8)	2,058.88	2,882.14	1,853.26	11,679.00
10. Tax expense *	661.26	876.86	613.96	3,838.86
11. Net Profit from Ordinary Activities after tax (9-10)	1,397.62	2,005.28	1,239.30	7,840.14
12. Extraordinary items (net of tax expense)	-	-	-	-
13. Net Profit for the period (11±12)	1,397.62	2,005.28	1,239.30	7,840.14
14. Paid-up equity share capital (Face Value Rs 10/-)	1,659.94	1,659.94	1,659.94	1,659.94
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	46,706.19
16.i Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):				
(a) Basic	8.42	12.08	7.47	47.23
(b) Diluted	8.42	12.08	7.47	47.23
16.ii Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised):				
(a) Basic	8.42	12.08	7.47	47.23
(b) Diluted	8.42	12.08	7.47	47.23
A PARTICULARS OF SHAREHOLDING				
1 Public shareholding				
- Number of shares	80,00,158	80,00,158	80,00,158	80,00,158
- Percentage of shareholding	48.2	48.2	48.2	48.2
2 Promoters and Promoter Group Shareholding				
(a) Pledged/ Encumbered				
- Number of shares	-	-	-	-
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	-	-	-	-
- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-
(b) Non-encumbered				
- Number of shares	85,99,224	85,99,224	85,99,224	85,99,224
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100	100	100	100
- Percentage of shares (as a % of the total share capital of the company)	51.8	51.8	51.8	51.8
* Tax expense consists of:				
Current Tax	780.00	890.00	630.00	3,850.00
Deferred Tax	(118.74)	(13.14)	(16.04)	(11.14)

Particulars	(Rs. in Lakh)			
	3 months ended 31/03/2013	Preceding 3 months ended 31/12/2012	Corresponding 3 months ended 31/03/2012 in the previous year	Previous year ended 31/12/2012
	Unaudited	Audited	Unaudited	Audited
1. Segment Revenue				
a) Pharmaceuticals	11,888.07	10,912.35	9,290.54	45,733.5
b) Chemicals	6,877.04	6,277.68	5,750.24	24,639.3
Total	18,765.11	17,190.03	15,040.78	70,372.8
Less: Inter segment revenue	561.43	433.39	403.84	1,644.9
Net Sales and Other Operating Income	18,203.68	16,756.64	14,636.94	68,727.9
2. Segment Results (Profit before Tax and Interest from each segment)				
a) Pharmaceuticals	1,029.74	1,586.01	713.36	6,554.6
b) Chemicals	569.74	763.03	719.43	3,199.0
Total	1,599.48	2,349.04	1,432.79	9,753.7
Less: Other un-allocable expenditure net of un-allocable income	(459.40)	(533.10)	(420.47)	(1,925.3
Total Profit before Tax	2,058.88	2,882.14	1,853.26	11,679.0
3. Capital Employed				
a) Pharmaceuticals	10,002.38	7,864.43	9,012.00	7,864.4
b) Chemicals	13,894.98	13,946.60	12,771.12	13,946.6
c) Unallocated	25,866.39	26,555.10	20,464.48	26,555.1
Total	49,763.75	48,366.13	42,247.60	48,366.1

Particulars	3 months ended 31/03/2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	3
Disposed of during the quarter	3
Remaining unresolved at the end of the quarter	Nil

Notes :-

- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 28th April, 2013. The above results were subjected to a "Limited Review" by the Statutory Auditors.
- Figures for the previous quarter/year have been re-grouped/re-arranged wherever necessary.
- Figures of the preceding 3 months ended December 31, 2012 are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures upto the third quarter of the previous financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.

Place : Mumbai
 Date : 28th April, 2013
 Please visit us at our website www.merck.co.in

For MERCK LIMITED


 Dr. Claus-Dieter Boedecker
 MANAGING DIRECTOR